ERBB2 and breast carcinoma: Breast cancer subtypes also exhibit different response to chemotherapy, with HER2+ and basal-like TNBC having higher response rates to cytotoxic agents (Krishnamurti et al., 2017; Li et al., 2017; Li et al., 2016; Li et al., 2016; Rouzier et al., 2005; Wright et al., 2017).